X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (79) 79
index medicus (67) 67
hematology (57) 57
female (40) 40
male (40) 40
oncology (39) 39
aged (34) 34
middle aged (31) 31
leukemia, lymphocytic, chronic, b-cell - drug therapy (28) 28
rituximab (28) 28
adult (27) 27
aged, 80 and over (24) 24
leukemia, lymphocytic, chronic, b-cell - pathology (23) 23
antineoplastic combined chemotherapy protocols - therapeutic use (22) 22
expression (16) 16
therapy (16) 16
chronic lymphocytic leukemia (15) 15
cll (15) 15
prognosis (15) 15
abridged index medicus (14) 14
chemotherapy (14) 14
fludarabine (14) 14
leukemia, lymphocytic, chronic, b-cell - genetics (14) 14
immunotherapy (13) 13
cancer (12) 12
cyclophosphamide (12) 12
previously untreated patients (12) 12
survival (12) 12
vidarabine - analogs & derivatives (12) 12
antineoplastic agents - therapeutic use (11) 11
chemoimmunotherapy (11) 11
chronic lymphocytic-leukemia (11) 11
hematology, oncology and palliative medicine (11) 11
treatment outcome (11) 11
leukemia, lymphocytic, chronic, b-cell - immunology (10) 10
leukemia, lymphocytic, chronic, b-cell - mortality (10) 10
minimal residual disease (10) 10
tumor cells, cultured (10) 10
apoptosis (9) 9
chronic lymphatic leukemia (9) 9
leukemia (9) 9
leukemia, lymphocytic, chronic, b-cell - metabolism (9) 9
alemtuzumab (8) 8
antineoplastic combined chemotherapy protocols - adverse effects (8) 8
b-cells (8) 8
chlorambucil (8) 8
clinical trials (8) 8
open-label (8) 8
cyclophosphamide - administration & dosage (7) 7
diagnosis (7) 7
disease-free survival (7) 7
fludarabine plus cyclophosphamide (7) 7
ibrutinib (7) 7
initial therapy (7) 7
leukemia, lymphocytic, chronic, b-cell - diagnosis (7) 7
medicine, research & experimental (7) 7
survival rate (7) 7
adolescent (6) 6
drug resistance, neoplasm (6) 6
flow cytometry (6) 6
follow-up studies (6) 6
leukemia, lymphocytic, chronic, b-cell - therapy (6) 6
lymphatic leukemia (6) 6
mutation (6) 6
neoplasm staging (6) 6
phase-ii trial (6) 6
resistance (6) 6
survival analysis (6) 6
antibodies, monoclonal, murine-derived - administration & dosage (5) 5
antineoplastic agents - administration & dosage (5) 5
antineoplastic agents - adverse effects (5) 5
cd8-positive t-lymphocytes - immunology (5) 5
combination (5) 5
combined modality therapy (5) 5
disease progression (5) 5
identification (5) 5
patients (5) 5
progression-free (5) 5
recurrence (5) 5
research (5) 5
rituximab - administration & dosage (5) 5
t cells (5) 5
trial (5) 5
vidarabine - administration & dosage (5) 5
activation (4) 4
animals (4) 4
antibodies, monoclonal - therapeutic use (4) 4
antibodies, monoclonal, humanized (4) 4
antibodies, monoclonal, murine-derived - therapeutic use (4) 4
antigens (4) 4
antimitotic agents (4) 4
antineoplastic agents (4) 4
antineoplastic combined chemotherapy protocols - administration & dosage (4) 4
article (4) 4
bendamustine (4) 4
chronic lymphocytic leukaemia (4) 4
cll cells (4) 4
cyclophosphamide - therapeutic use (4) 4
drug administration schedule (4) 4
neoplasm, residual - diagnosis (4) 4
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Blood, ISSN 0006-4971, 05/2019, Volume 133, Issue 19, pp. 2003 - 2004
In this issue of Blood, Byrd et al report that after nearly 4 years of follow-up, there is an impressive and sustained progression-free survival and overall... 
HEMATOLOGY | RITUXIMAB
Journal Article
Haematologica, ISSN 0390-6078, 03/2018, Volume 103, Issue 4, pp. 563 - 564
Journal Article
The Lancet Haematology, ISSN 2352-3026, 08/2019, Volume 6, Issue 8, pp. e389 - e390
Journal Article
Blood, ISSN 0006-4971, 02/2014, Volume 123, Issue 9, pp. 1282 - 1284
Journal Article
BLOOD, ISSN 0006-4971, 02/2014, Volume 123, Issue 9, pp. 1282 - 1284
In this issue of Blood, Byrd et al present first-in-man data in chronic lymphocytic leukemia (CLL) using otlertuzumab (TRU-016), a fully humanized anti-CD37... 
HEMATOLOGY | CHRONIC LYMPHOCYTIC-LEUKEMIA | PROTEIN | Antineoplastic Agents - adverse effects | Recombinant Fusion Proteins - adverse effects | Humans | Female | Male | Antineoplastic Agents - administration & dosage | Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy | Immunoglobulin G - adverse effects
Journal Article
Blood, ISSN 0006-4971, 2016, Volume 128, Issue 13, pp. 1711 - 1722
Journal Article
DMW - Deutsche Medizinische Wochenschrift, ISSN 0012-0472, 04/2015, Volume 140, Issue 7, pp. 479 - 482
Was ist neu? Diagnostik: Die Diagnose wird aus einer durchflusszytometrischen Analyse des peripheren Blutes gestellt, eine diagnostische Knochenmarkpunktion... 
Klinischer Fortschritt | TP53 mutation | immunochemotherapy | targeted treatment
Journal Article
Blood, ISSN 0006-4971, 01/2016, Volume 127, Issue 2, pp. 208 - 215
Journal Article
DMW - Deutsche Medizinische Wochenschrift, ISSN 0012-0472, 07/2016, Volume 141, Issue 14, pp. 1000 - 1000
Journal Article
Deutsche Zeitschrift fur Onkologie, ISSN 1617-5891, 2014, Volume 46, Issue 2, pp. 78 - 79
Journal Article
DMW - Deutsche Medizinische Wochenschrift, ISSN 0012-0472, 06/2016, Volume 141, Issue 11, pp. 768 - 771
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 6, pp. 768 - 778
Journal Article
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 09/2011, Volume 29, Issue 26, pp. 3559 - 3566
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 7, pp. 928 - 942
Journal Article
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.